Table 1.
Baseline characteristics of admitted COVID-19 diagnosed patients
| Admitted | Admitted to ICU | 30-day follow-up | ||
|---|---|---|---|---|
| Variable | Total | Survivors | Non-survivors | |
| N (%) | 2431 | 359 (14.8%) | 1976 (81.3%) | 455 (18.7%) |
| Age in years, Median (IQR, 25–75%) | 69 (53–80) | 69 (59–75) | 64 (49–77) | 81 (74–86.5) |
| Sex (%) | ||||
| Female | 1116 (45.9%) | 106 (29.5%) | (47.5%) | 178 (39.1%) |
| Male | 1315 (54.1%) | 253 (70.5%) | 1038 (52.5%) | 277 (60.9%) |
| Age in age groups, year (%) | ||||
| 0–64 | 1039 (42.7%) | 135 (37.6%) | 1016 (51.4%) | 23 (5.1%) |
| 65–84 | 1072 (44.1%) | 212 (59.1%) | 790 (40.0%) | 282 (62.0%) |
| 85+ | 320 (13.2%) | 12 (3.34%) | 170 (8.6%) | 150 (33.0%) |
| Admissions and duration | ||||
|
Median duration of hospitalizations > 12 h in days (IQR) |
5.47 (2.2–11.11) | 19.38 (10.42–29.05) | 5.19 (1.6–10.55) | 7.02 (3.35–11.48) |
| Patients needing | ||||
| ICU admission | 359 (14.8%) | 359 (100%) | 252 (12.8%) | 107 (23.5%) |
| Mechanical respirator use | 240 (9.9%) | 240 (66.9%) | 167 (8.5%) | 73 (16.0%) |
| ECMO | 18 (0.7%) | 18 (5%) | 13 (0.7%) | 5 (1.1%) |
| Dialysis | 78 (3.2%) | 78 (21.7%) | 48 (2.4%) | 30 (6.6%) |
| Inotropic/Vasopressor use | 210 (8.6%) | 210 (58.5%) | 143 (7.2%) | 67 (14.7%) |
| Comorbidities*** | ||||
| Any comorbidities | 1475 (60.7%) | 225 (62.7%) | 1086 (55.0%) | 389 (85.5%) |
| Cardiovascular disease | ||||
| Myocardial infarct | 122 (5%) | 22 (6.1%) | 83 (4.2%) | 39 (8.6%) |
| Hypertension | 412 (16.9%) | 55 (15.3%) | 294 (14.9%) | 118 (25.9%) |
| Congestive heart failure | 175 (7.2%) | 19 (5.3%) | 114 (5.8%) | 61 (13.4%) |
| Peripheral vascular disease | 144 (5.9%) | 30 (8.4%) | 93 (4.7%) | 51 (11.2%) |
| Cerebrovascular diseases | 259 (10.7%) | 28 (7.8%) | 176 (8.9%) | 83 (18.2%) |
| Chronic respiratory disease | 298 (12.3%) | 45 (12.5%) | 219 (11.1%) | 79 (17.4%) |
| Asthma | 122 (5.0%) | 20 (5.6%) | 108 (5.5%) | 14 (3.1%) |
| COPD | 216 (8.9%) | 36 (10.0%) | 143 (7.2%) | 73 (16%) |
| Immunosuppression | 459 (18.9%) | 84 (23.4%) | 327 (16.5%) | 132 (29%) |
| Of which cancer | 324 (13.3%) | 64 (17.8%) | 234 (11.8%) | 90 (19.8%) |
| Kidney disease | 130 (5.3%) | 22 (6.1%) | 79 (4.0%) | 51 (11.2%) |
| Rheumatologic disease/Connective tissue disease | 104 (4.3%) | 17 (4.7%) | 78 (3.9%) | 26 (5.7%) |
| Liver disease | 51 (2.1%) | 10 (2.8%) | 43 (2.2%) | 8 (1.8%) |
| Metabolic disease | ||||
| Diabetes | 315 (13.0%) | 55 (15.3%) | 225 (11.4%) | 90 (19.8%) |
| Obesity | 135 (5.6%) | 23 (6.4%) | 112 (5.7%) | 23 (5.1%) |
| Neurological disease | 271 (11.1%) | 38 (10.6%) | 206 (10.4%) | 65 (14.3%) |
| Comorbidity level (CCI) | ||||
| 0 (reference) | 1440 (59.2%) | 201 (56.0%) | 1281 (64.8%) | 159 (34.9%) |
| 1 to 2 | 703 (28.9%) | 118 (32.9%) | 512 (25.9%) | 191 (42.0%) |
| > 2 | 287 (11.8%) | 40 (11.1%) | 182 (9.2%) | 105 (23.1%) |
Groups with less than five patients are presented as < 5
* Values expressed as total number (fraction) and medians [25 percentile-75 percentile] as appropriate. Chi-squared test for categorical variables and Kruskal-Wallis test for continuous variables
**Readmission is defined as a hospital contact at least 24 h after a previous hospital contact and a duration of 12 h or more
*** Any hospital contacts in the past 10 years